Engineering CAR-T cells for solid tumors: bispecific antigen targeting, tumor microenvironment modulation, and...

Area of Science:

• Immunotherapy
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor T (CAR-T) cell therapy has transformed hematologic cancer treatment.
• Significant challenges hinder CAR-T efficacy in solid tumors, including antigen heterogeneity, immunosuppressive tumor microenvironments, and toxicity.

Purpose of the Study:

• To review recent advancements in CAR-T cell therapy for solid tumors.
• To highlight innovations in CAR-T design, delivery systems, and safety mechanisms.

Main Methods:

• Review of CAR-T generations, co-stimulatory domains, and cytokine-armed TRUCKs.
• Comparison of viral and non-viral delivery systems (e.g., CRISPR, mRNA electroporation).
• Discussion of strategies to overcome solid tumor barriers, including dual-targeting, tumor-restricted CARs, and TME modulation.

Main Results:

• Next-generation CAR-T designs incorporate nanobodies and advanced safety switches (e.g., iCasp9).
• CRISPR technology enables multiplex gene editing for enhanced CAR-T specificity.
• Armored CARs and engineered chemokine receptors improve tumor infiltration and microenvironment remodeling.

Conclusions:

• CAR-T therapy for solid tumors shows promise through advanced designs and delivery systems.
• Overcoming manufacturing complexity, off-target effects, and regulatory hurdles is crucial for clinical translation.
• Future directions include AI-driven design and personalized neoantigen targeting for CAR-T 2.0.